Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension

Cattazzo, Filippo; Lombardi, Rosa; Mantovani, Alessandro; Bevilacqua, M.; Zoncapè, Mirko; Prat, Laura Iogna; Roccarina, Davide; Fortuna, L.; Cespiati, Annalisa; Sacerdoti, David; Tsochatzis, Emmanuel; Fava, Cristiano; Dalbeni, Andrea

doi:10.1016/j.numecd.2022.08.005

Cited by 4 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The key pathophysiological pathways linking NAFLD and coronary atherosclerosis are supposed to be insulin resistance [ 16 ], subclinical inflammation [ 16 ], endothelial dysfunction [ 17 ], and changed lipid profiles (atherogenic dyslipidemia) [ 18 ]. When NAFLD and hypertension coexist, early vascular alterations resulting in vascular damage have been reported [ 19 ], and the level of inflammation and insulin resistance were higher when diabetes coexisted with hepatic steatosis [ 20 ]. Thus, it is not surprising to see that an increased risk of CAC progression is evident in participants with MASLD, who have metabolic dysfunction, but not in those with cryptogenic SLD.…”

Section: Discussionmentioning

confidence: 99%

“…(atherogenic dyslipidemia) [18]. When NAFLD and hypertension coexist, early vascular alterations resulting in vascular damage have been reported [19], and the level of inflammation and insulin resistance were higher when diabetes coexisted with hepatic steatosis [20]. Thus, it is not surprising to see that an increased risk of CAC progression is evident in participants with MASLD, who have metabolic dysfunction, but not in those with cryptogenic SLD.…”

Section: Plos Onementioning

confidence: 99%

See 1 more Smart Citation

Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score

Kim,

Kang,

Choi

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background & aims A new nomenclature, Steatotic Liver Disease (SLD), has been proposed by consensus with sub-classifications and requires evidence-based validation. We assessed whether the presence and severity of SLD, as well as its sub-classifications, are associated with the progression of coronary atherosclerosis. Methods This longitudinal cohort study included 13,811 adults who participated in repeated regular health screening examinations between January 1, 2004 and December 31, 2021 that included assessments of their coronary artery calcium (CAC) scores. SLD was defined using abdominal ultrasonography and classified as metabolic dysfunction associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. SLD severity was assessed using fibrosis-4 (FIB-4) scores. The progression of CAC scores was measured using multidetector CT scans. Results The average duration of follow-up was 5.8 years. During follow-up, the annual rate of CAC progression in participants with and without SLD was 18% (95% CI 17%–19%) and 14% (95% CI 13%–14%) (p < 0.01), respectively. The multivariable ratios of progression rates when we compared participants with cryptogenic SLD, MASLD, or MetALD with those without SLD were 0.98 (95% CI 0.95–1.01), 1.03 (95% CI 1.03–1.04), and 1.07 (95% CI 1.04–1.09), respectively. The multivariable ratios of progression rates when we compared participants with SLD with FIB-4 score <1.3 and SLD with FIB-4 score ≥1.3 with those without SLD were 1.03 (95% CI 1.02–1.04), and 1.05 (95% CI 1.04–1.06), respectively. Conclusions SLD was associated with a higher risk of coronary atherosclerosis, and the risk differed by sub-classifications and severity. These findings suggest that the newly proposed definition has clinical relevance in terms of stratifying cardiovascular disease risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Plos Onementioning

confidence: 99%

Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score

Kim,

Kang,

Choi

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…These are key mechanisms in the development and progression of atherosclerosis ( VanWagner, 2018 ). People with NAFLD have been shown to have a high probability of atherosclerosis ( Cattazzo et al, 2022 ). They often go to the liver disease centers of various hospitals for treatment.…”

Section: Materials and Methodologymentioning

confidence: 99%

Early prediction of atherosclerosis diagnosis with medical ambient intelligence

et al. 2023

View full text Add to dashboard Cite

Atherosclerosis is a chronic vascular disease that poses a significant threat to human health. Common diagnostic methods mainly rely on active screening, which often misses the opportunity for early detection. To overcome this problem, this paper presents a novel medical ambient intelligence system for the early detection of atherosclerosis by leveraging clinical data from medical records. The system architecture includes clinical data extraction, transformation, normalization, feature selection, medical ambient computation, and predictive generation. However, the heterogeneity of examination items from different patients can degrade prediction performance. To enhance prediction performance, the “SEcond-order Classifier (SEC)” is proposed to undertake the medical ambient computation task. The first-order component and second-order cross-feature component are then consolidated and applied to the chosen feature matrix to learn the associations between the physical examination data, respectively. The prediction is lastly produced by aggregating the representations. Extensive experimental results reveal that the proposed method’s diagnostic prediction performance is superior to other state-of-the-art methods. Specifically, the Vitamin B12 indicator exhibits the strongest correlation with the early stage of atherosclerosis, while several known relevant biomarkers also demonstrate significant correlation in experimental data. The method proposed in this paper is a standalone tool, and its source code will be released in the future.

show abstract

“…The latter include atherosclerotic manifestations (thickening of the intima-media, endothelial dysfunction, and increased arterial stiffness), left ventricular hypertrophy, calcification of the aortic valve and coronary arteries [ 15 , 16 ]. The comorbidity of NAFLD and AH significantly increases the risk of atherosclerosis compared to what is observed in the presence of only one of these diseases [ 17 ].…”

Section: Prognoses Of Patients With Nafld and Ahmentioning

confidence: 99%

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Golubeva,

Sheptulina,

Elkina

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

show abstract

Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension

Cited by 4 publications

References 62 publications

Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score

Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score

Early prediction of atherosclerosis diagnosis with medical ambient intelligence

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Contact Info

Product

Resources

About